Buyck Julien M, Tulkens Paul M, Van Bambeke Françoise
Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
Antimicrob Agents Chemother. 2015 Jan;59(1):258-68. doi: 10.1128/AAC.04011-14. Epub 2014 Oct 27.
Antibiotic combinations are often used for treating Pseudomonas aeruginosa infections but their efficacy toward intracellular bacteria has not been investigated so far. We have studied combinations of representatives of the main antipseudomonal classes (ciprofloxacin, meropenem, tobramycin, and colistin) against intracellular P. aeruginosa in a model of THP-1 monocytes in comparison with bacteria growing in broth, using the reference strain PAO1 and two clinical isolates (resistant to ciprofloxacin and meropenem, respectively). Interaction between drugs was assessed by checkerboard titration (extracellular model only), by kill curves, and by using the fractional maximal effect (FME) method, which allows studying the effects of combinations when dose-effect relationships are not linear. For drugs used alone, simple sigmoidal functions could be fitted to all concentration-effect relationships (extracellular and intracellular bacteria), with static concentrations close to (ciprofloxacin, colistin, and meropenem) or slightly higher than (tobramycin) the MIC and with maximal efficacy reaching the limit of detection in broth but only a 1 to 1.5 (colistin, meropenem, and tobramycin) to 2 to 3 (ciprofloxacin) log10 CFU decrease intracellularly. Extracellularly, all combinations proved additive by checkerboard titration but synergistic using the FME method and more bactericidal in kill curve assays. Intracellularly, all combinations proved additive only based on both FME and kill curve assays. Thus, although combinations appeared to modestly improve antibiotic activity against intracellular P. aeruginosa, they do not allow eradication of these persistent forms of infections. Combinations including ciprofloxacin were the most active (even against the ciprofloxacin-resistant strain), which is probably related to the fact this drug was the most effective alone intracellularly.
抗生素联合用药常用于治疗铜绿假单胞菌感染,但迄今为止其对细胞内细菌的疗效尚未得到研究。我们研究了主要抗假单胞菌类药物(环丙沙星、美罗培南、妥布霉素和黏菌素)的代表药物组合对THP-1单核细胞模型中细胞内铜绿假单胞菌的作用,与肉汤中生长的细菌进行比较,使用参考菌株PAO1和两个临床分离株(分别对环丙沙星和美罗培南耐药)。通过棋盘滴定法(仅细胞外模型)、杀菌曲线以及使用分数最大效应(FME)方法评估药物之间的相互作用,该方法允许在剂量-效应关系非线性时研究联合用药的效果。对于单独使用的药物,所有浓度-效应关系(细胞外和细胞内细菌)都可以拟合简单的S形函数,静态浓度接近(环丙沙星、黏菌素和美罗培南)或略高于(妥布霉素)最低抑菌浓度(MIC),肉汤中的最大疗效达到检测极限,但细胞内仅使细菌数量减少1至1.5(黏菌素、美罗培南和妥布霉素)至2至3(环丙沙星)个对数10CFU。在细胞外,通过棋盘滴定法所有联合用药均显示为相加作用,但使用FME方法时为协同作用,并且在杀菌曲线试验中更具杀菌作用。在细胞内,仅基于FME和杀菌曲线试验所有联合用药均显示为相加作用。因此,尽管联合用药似乎适度提高了对细胞内铜绿假单胞菌的抗生素活性,但它们并不能根除这些持续性感染形式。包括环丙沙星的联合用药最为有效(甚至对环丙沙星耐药菌株),这可能与该药物在细胞内单独使用时最有效这一事实有关。